Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Recurrent or metastatic head and neck squamous cell carcinoma
What changed

Recurrent or metastatic head and neck squamous cell carcinoma

What changed: Recurrent or metastatic head and neck squamous cell carcinoma

Cancer page →

Every dated change on the records linked to Recurrent or metastatic head and neck squamous cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Trial result8Milestone7This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordRecurrent or metastatic head and neck squamous cell carcinoma
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 1

2026Trial resultMETRO PLUS (Tata Memorial Centre, Varanasi)
METRO PLUS (Tata Memorial Centre, Varanasi) reported
Median OS 10 vs 5 months, HR 0.

2025 · 1

2025MilestonePetosemtamab
Petosemtamab with pembrolizumab: phase 2 responses in about six in ten; phase 3 under way
A milestone in how this cancer is treated.

2023 · 2

2023Trial resultLow-dose nivolumab plus metronomic chemotherapy (Tata Memorial)
Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial) reported
1-year OS 43.
2023MilestoneLow-dose nivolumab plus metronomic chemotherapy (Tata Memorial)
Tata Memorial: low-dose nivolumab nearly triples one-year survival
A milestone in how this cancer is treated.

2021 · 1

2021Trial resultTPExtreme (GORTEC 2014-01)
TPExtreme (GORTEC 2014-01) reported
TPEx did not improve overall survival over EXTREME, but gave similar survival with a shorter schedule and less toxicity.

2020 · 2

2020Trial resultOral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)
Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial) reported
Median OS 7.
2020MilestoneOral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)
Tata Memorial: oral metronomic chemotherapy beats cisplatin
A milestone in how this cancer is treated.

2019 · 2

2019Trial resultKEYNOTE-048
KEYNOTE-048 reported
OS 14.
2019MilestoneKEYNOTE-048
KEYNOTE-048: pembrolizumab first line
A milestone in how this cancer is treated.

2016 · 2

2016Trial resultCheckMate 141
CheckMate 141 reported
OS 7.
2016MilestoneCheckMate 141
CheckMate 141: nivolumab after platinum
A milestone in how this cancer is treated.

2008 · 2

2008Trial resultEXTREME
EXTREME reported
OS 10.
2008MilestoneEXTREME
EXTREME: first survival gain in recurrent disease
A milestone in how this cancer is treated.

2006 · 2

2006Trial resultBonner trial (cetuximab plus radiotherapy)
Bonner trial (cetuximab plus radiotherapy) reported
Median overall survival 49.
2006MilestoneCetuximab
Cetuximab approved for head and neck cancer
A milestone in how this cancer is treated.